AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06373250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: You will be asked to fill in an information form to be admitted to the Primipar participating maternity unit. No membrane stripping are applied and no cervical interventions are made during the birth process. A visual analog scale will be completed before and after each vaginal examination. During the vaginal examination, the Bishop scoring form will be filled out. The average of the VAS and Bishop scores obtained during the vaginal examinations will be taken. At four hours postpartum, the pads are weighed and the amount of bleeding is recorded on the form. You will also be asked to complete the short form of the Birth Satisfaction Scale.
Study NCT06710145 — intervention group
Intervention type: BEHAVIORAL
Intervention: Combat Attention Training
Description: The Combat Attention App is a response-time based mechanized preventive intervention designed to train combat soldiers' attention toward threats before combat exposure in order to reduce the risk for combat-related post-trauma symptoms. In light of the results of controlled studies that proved the efficacy of this preventive intervention, the Israel Defense Forces (IDF) decided at the beginning of the Iron Swords War (October 7th, 2023) to implement an internet-based App of the intervention, and soldiers and combat reservists were invited to train on the Combat Attention App.
Study NCT06708806 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Description: bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (XY1) vs. an toric IOL (XY1A)
Study NCT06707415 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Auditory evoked potentials
Description: Auditory evoked potentials in parallel systems
Study NCT05212194 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: examination
Description: Joint laxity is scored according to the level of motion in 5 different joints and a maximum of 9 points is obtained.
Study NCT04914923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muse
Description: Muse is an EEG headset device created by Interaxxon to track brain waves during mindfulness sessions.
Study NCT04897503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Corneal epithelium removed followed by riboflavin drop administration (riboflavin/dextran -vs- riboflavin/methylcellulose) every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive either the riboflavin/dextran solution or the riboflavin/HPMC solution.
Study NCT05314595 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral uterine artery ligation
Description: * Spinal anaethesia with intrathecal morphia~* Transverse skin incision~* Adequate dissection of the bladder.~* Incision of the uterus above placental edge.~* Delivery of the fetus.~* Delayed cord clamping (60 seconds) if the baby appears well.~* Exteriorization of the uterus.~* Start Oxytocin infusion and uterine massage to ensure good uterine contractions immediately after delivery of the fetus. No trials of placental delivery will be made at this point.~* At this point, a gentile trial to deliver the placenta is performed~* A catheter is placed in the cervix from above to secure the cervical opening~* Compression is applied to the site of bleeding from placenta site~* Placental pouch is marked by multiple allies and is closed down to the multiple-8 suture.~* Blood loss is measured using the suction device and coated socked towels. In modified PPC, Bilateral uterine artery ligation will be done after exteriorization of the uterus in order to minimize the blood loss.
Study NCT06637839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Locomotor Training Program
Description: The high-intensity program prescribes participants to exert at least 60% of their heart rate (HR) reserve, or a score of 16-18 on the RPE scale.
Study NCT04611126 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg is administered 2-6 weeks before surgical removement of the tumor. The medicine is administered i.v. over 30 minutes.
Study NCT04611126 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamid
Description: Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
Study NCT06637839 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Step Count Locomotor Training Program
Description: The high step count program prescribes at least 600 steps per session, at less than 50% or HR reserve, or less than 13 RPE.
Study NCT06642233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Socio-demographic survey
Description: Socio-demographic survey includes: age, sex, time of symptoms, work activity, hours of work activity, work position, activities with loads, physical activity, household chores, missing teeth, dental splints, dentures, smoking, alcohol consumption, whether they can reproduce their symptoms, hours during which they perform focal distance tasks, whether they have visual problems, whether they take painkillers or anti-inflammatory drugs, presence of headaches and their frequency), whether you can reproduce your symptoms, hours during which you perform tasks at focal distance, whether you have visual problems, whether you take analgesics or anti-inflammatory drugs, presence and frequency of headaches.
Study NCT06642233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Analogue Scale
Description: VAS scale - The subject must indicate with a horizontal line their perception of pain on a scale (not numbered) of 100 millimetres, with 0 being the absence of pain and 100 the worst pain imaginable. The patient will complete the VAS scale, responding to the average, maximum and minimum pain experienced throughout its duration.
Study NCT06642233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The World Health Organization Quality-of-Life Scale-BREF questionnaire
Description: The WHOQOL-BREF questionnaire is used to assess domains quality of life: physical, mental, social functioning and functioning in the environment. Responses are on a 5-point scale (score range 1-5). In each field you can get maximum 20 points. The results of individual areas are positive (the higher the number of points, the higher the quality of life).
Study NCT06642233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The International Physical Activity Questionnaire
Description: The International Physical Activity Questionnaire (IPAQ) is a self-reported questionnaire for assessing physical activity and sedentary behavior for adults aged 15-69 years, across a range of socio-economic settings.
Study NCT04611126 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine Phosphate
Description: Fludarabine 25 mg/m2 is administered on day -5 to day -1.
Study NCT04611126 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Tumor Infiltrating Lymphocytes infusion
Description: Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion. The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
Study NCT04611126 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab
Description: Nivolumab 240 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 30 minutes.
Study NCT04914923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Description: Cognitive behavioural therapy (CBT), incorporating exposure/response prevention (ERP) and cognitive therapy, is considered the gold-standard treatment for OCD. The efficacy of CBT has been well established, with numerous studies demonstrating that it leads to significant and lasting reduction in OCD symptoms for the majority of completers.
Study NCT04914923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Description: Mindfulness-based interventions (MBIs) including MBCT, are interventions that incorporate formal and informal mindfulness practice in order to treat mental health concerns.
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: Liquid solution - intramuscular
Study NCT04611126 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Relatlimab
Description: Relatlimab 80 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 60 minutes.
Study NCT06642233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The Neck Disability Index questionnaire
Description: The NDI evaluates the effect of neck pain on activities of daily living and social relationships. It consists of 10 items with 6 response options that are scored from 0 to 5 points each for a total possible score of 50. The classification of disability is based on the total score obtained, with higher number indicating greater disability.
Study NCT06642233 — intervention group
Intervention type: DEVICE
Intervention: Body composition analysis using TANITA device
Description: TANITA device - body composition analyzer, the proportion of muscle mass and fat in the upper limbs~* Body height will be determined using a SECA 217 stadimeter.~* General and segmental body composition using the eight-electrode body composition analyzer by TANITA.
Study NCT06642233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cervical spine AROM (Active range of motion)
Description: Measurement of cervical spine AROM can be performed using the CROM system (Performance Attainment Associates, Roseville, MN, USA). Flexion, extension, side bending to the right and left, and rotation to the right and left of the cervical spine are examined.~The CROM measuring equipment consists of a helmet-shaped structure with the shape of glasses. These glasses adjust to the nasal septum thanks to the velcro on the back to fit them on the head. Three inclinometers for measuring on 3 cardinal planes were placed in the plastic construction.
Study NCT06642233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sagittal plane UCS AROM (Upper cervical spine active range of motion)
Description: Measurement of sagittal plane UCS AROM can be performed using the CROM system. Flexion and extension of the upper cervical spine are examined.
Study NCT06642233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flexion-Rotation Test
Description: The flexion-rotation test can be performed using the CROM system. Rotation of the upper cervical spine is tested while the cervical spine is flexed.
Study NCT06642233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sidebending-Rotation Test
Description: The sidebending-rotation test can be performed using the CROM system. Rotation of the upper cervical spine is tested while the cervical spine is in a lateral tilt.
Study NCT06642233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Axial rotation test C0-C2
Description: The Axial rotation test C0-C2 can be performed using the CROM system. Rotation of the C0-C2 is examined.
Study NCT06642233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tilting test C0-C1 and C2-C3
Description: The Tilting test C0-C1 and C2-C3 can be performed using a goniometer. Lateral tilt of the C0-C1 and C2-C3 are examined.
Study NCT06642233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Craniocervical flexion test
Description: The test measures the level of activation of the deep neck flexors using a pressure biofeedback device, an air-filled manual pressure cuff (Stabilizer TM, Chattanooga Group, INC., USA).
Study NCT06642233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Craniovertebral angle
Description: The test measure the craniovertebral angle using a telephone placed on a tripod and a computer program. The CVA measurement is defined as the angle a horizontal line passing the neural spine of C7 in relation to the line connecting the tragus and the neural spine of C7.
Study NCT06644976 — intervention group
Intervention type: PROCEDURE
Intervention: femoral neck CRIF
Description: femoral neck fracture CRiF while under noac. no special intervention beside taking blood test for drug levels
Study NCT06643806 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHAI dyad study
Description: In the CHAI (Cardiovascular Health among Asian Indian immigrants) Dyad study, we plan to Implement and pilot test a peer leader-facilitated 12-week dyadic intervention to decrease CVD risk among first generation AI immigrants;
Study NCT06643806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAI dyad study
Description: In the CHAI (Cardiovascular Health among Asian Indian immigrants) Dyad study, we plan to Implement and pilot test a peer leader-facilitated 12-week dyadic intervention to decrease CVD risk among first generation AI immigrants;
Study NCT05804084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide tablet (encapsulated)
Study NCT05804084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar capsule manufactured to match encapsulated Acetazolamide
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: Liquid solution - intramuscular
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)
Description: Oral suspension - oral
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)
Description: Oral suspension - oral
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)
Description: Oral suspension - oral
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumoccocal Vaccine
Description: Suspension for injection - intramuscular
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumoccocal Vaccine
Description: Suspension for injection - intramuscular
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumoccocal Vaccine
Description: Suspension for injection - intramuscular
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, Mumps, and Rubella Vaccine live (MMR)
Description: Lyophilized powder for injection - subcutaneous
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measles, Mumps, and Rubella Vaccine live (MMR)
Description: Lyophilized powder for injection - subcutaneous
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, and Rubella Vaccine live (MMR)
Description: Lyophilized powder for injection - subcutaneous
Study NCT05109559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full dose of Ad26.COV2. 5x10^10vp
Description: A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTwP-HepB-Hib-IPV vaccine
Description: Suspension - intramuscular
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DTwP-HepB-Hib-IPV vaccine
Description: Suspension - intramuscular
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTwP-HepB-Hib-IPV vaccine
Description: Suspension - intramuscular
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV-Hib-HepB vaccine
Description: Liquid solution - intramuscular
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hib-HepB vaccine
Description: Liquid solution - intramuscular
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DTaP-IPV-Hib-HepB vaccine
Description: Liquid solution - intramuscular
Study NCT05109559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Half dose of Ad26.COV2. 2.5x10^10vp
Description: A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
Study NCT05109559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full dose of Ad26.COV2. 5x10^10vp
Description: A booster dose (2nd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Lyophilized powder for injection - subcutaneous
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis A vaccine
Description: Lyophilized powder for injection - subcutaneous
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Description: Lyophilized powder for injection - subcutaneous
Study NCT06371482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is an immunoglobulin G (IgG) 1-κsubtype monoclonal antibody (mAb) that blocks the interaction of PD-L1 with PD-1 in T cells and CD80 (B7.1) in immune cells (ics). Durvalumab is developed by Astrazeneca /MedImmune for the treatment of cancer. Durvalumab is designed to reduce the cytotoxicity of antibody-dependent cells and complement dependent cytotoxicity. In vitro studies have demonstrated that Durvalumab can antagonize the inhibition of PD-L1 in human primary T cells, causing them to resume proliferation and release interferon gamma (IFNγ). To date, more than 1,800 patients have been treated with valiuzumab as a single agent or in combination with other cancer agents as part of ongoing studies. Durvalumab: 10mg/Kg, intravenously, starting at week 7 every 3 weeks for at least 1 year, or until progression, intolerance, or spontaneous withdrawal of the patient.
Study NCT06371482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug of EP regimen
Description: Etoposide: 80-100mg/m², intravenous infusion, given at week 1, 4, 7, 10, 13, 16, a total of 6 cycles.~Carboplatin: AUC=5-6, intravenous infusion, given at weeks 1, 4, 7, 10, 13, 16, a total of 6 weeks. Or cisplatin: 75-80mg/m2 intravenously, given at weeks 1, 4, 7, 10, 13, 16 for a total of 6 weeks.
Study NCT06371482 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy: Total dose of 60Gy/30 times, each time 2.0Gy, 5 times a week from week 7 to week 12 of radiotherapy.
Study NCT06170060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy
Description: Laparoscopic sleeve gastrectomy (LSG) is a surgical procedure widely used in the treatment of obesity. It's a bariatric procedure, meaning its primary aim is to induce weight loss, and it has gained popularity due to its effectiveness and relatively low complication rates compared to other bariatric surgeries.
Study NCT04906382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT04906382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04906382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotavirus vaccine
Description: Oral solution - oral
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Rotavirus vaccine
Description: Oral solution - oral
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine
Description: Oral solution - oral
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid conjugate vaccine (TCV)
Description: Suspension for injection - intramuscular
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Typhoid conjugate vaccine (TCV)
Description: Suspension for injection - intramuscular
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid conjugate vaccine (TCV)
Description: Suspension for injection - intramuscular
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles vaccine
Description: Freeze-dried powder for reconstitution and injection - subcutaneous
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles vaccine
Description: Freeze-dried powder for reconstitution and injection - subcutaneous
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measles vaccine
Description: Freeze-dried powder for reconstitution and injection - subcutaneous
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella vaccine live
Description: Sterile powder and diluent for injection - subcutaneous
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Varicella vaccine live
Description: Sterile powder and diluent for injection - subcutaneous
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella vaccine live
Description: Sterile powder and diluent for injection - subcutaneous
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella vaccine live
Description: Lyophilized powder for injection - subcutaneous
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella vaccine live
Description: Lyophilized powder for injection - subcutaneous
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Varicella vaccine live
Description: Lyophilized powder for injection - subcutaneous
Study NCT05794230 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Suspension for injection - intramuscular